PMC:7784786 / 6453-7094 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"234","span":{"begin":21,"end":31},"obj":"Chemical"},{"id":"235","span":{"begin":167,"end":177},"obj":"Chemical"},{"id":"236","span":{"begin":390,"end":400},"obj":"Chemical"},{"id":"237","span":{"begin":517,"end":527},"obj":"Chemical"},{"id":"238","span":{"begin":139,"end":155},"obj":"Disease"},{"id":"239","span":{"begin":342,"end":358},"obj":"Disease"}],"attributes":[{"id":"A234","pred":"tao:has_database_id","subj":"234","obj":"MESH:C000597346"},{"id":"A235","pred":"tao:has_database_id","subj":"235","obj":"MESH:C000597346"},{"id":"A236","pred":"tao:has_database_id","subj":"236","obj":"MESH:C000597346"},{"id":"A237","pred":"tao:has_database_id","subj":"237","obj":"MESH:C000597346"},{"id":"A238","pred":"tao:has_database_id","subj":"238","obj":"MESH:D010996"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"MESH:D010996"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Patient 1 (A) Before itolizumab (D0): diffuse Interstitial-alveolar infiltrate in both lung fields, predominantly in the bases. Minor left pleural effusion. (B) After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. The minor pleural effusion persists. Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T17","span":{"begin":139,"end":155},"obj":"Phenotype"},{"id":"T18","span":{"begin":342,"end":358},"obj":"Phenotype"}],"attributes":[{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002202"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002202"}],"text":"Patient 1 (A) Before itolizumab (D0): diffuse Interstitial-alveolar infiltrate in both lung fields, predominantly in the bases. Minor left pleural effusion. (B) After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. The minor pleural effusion persists. Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs."}

{"project":"LitCovid-sentences","denotations":[{"id":"T59","span":{"begin":0,"end":127},"obj":"Sentence"},{"id":"T60","span":{"begin":128,"end":331},"obj":"Sentence"},{"id":"T61","span":{"begin":332,"end":368},"obj":"Sentence"},{"id":"T62","span":{"begin":369,"end":641},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Patient 1 (A) Before itolizumab (D0): diffuse Interstitial-alveolar infiltrate in both lung fields, predominantly in the bases. Minor left pleural effusion. (B) After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. The minor pleural effusion persists. Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs."}